A Phase 1, Open-Label, Drug-Interaction Study to Evaluate the Effect of Clarithromycin, a Potent CYP3A4 Inhibitor, on the Systemic Exposure of Pacritinib in Healthy Subjects
Overview
- Phase
- Phase 1
- Intervention
- Pacritinib
- Conditions
- Drug Interaction Study
- Sponsor
- CTI BioPharma
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Estimate ratios of geometric mean values and the corresponding 90% confidence intervals (CIs) for pacritinib treatments with and without clarithromycin
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This will be an open-label, single-center, crossover, one-way, drug-interaction study to evaluate the effect of 500 mg clarithromycin BID (dosed to steady state) on the PK of a single 400-mg dose of pacritinib in healthy male and female subjects.
Detailed Description
This was a single-center, open-label, one-way crossover, drug-interaction study. On Day 1, subjects received a single oral 400-mg dose of pacritinib. On Day 8 through the morning of Day 12, following a 7-day washout period, 500-mg oral doses of clarithromycin were administered twice daily (BID), 8 to 12 hours apart. It was anticipated that steady-state concentrations of clarithromycin would be achieved by Day 12. On Day 12, a single oral 400-mg dose of pacritinib was co-administered with the final 500-mg dose of clarithromycin.
Investigators
Eligibility Criteria
Inclusion Criteria
- •males or females, between 18 and 55 years of age, inclusive;
- •BMI between 18.5 and 32.0 kg/m2, inclusive;
- •in good health, determined by no clinically significant findings from medical history, physical examination, and vital signs;
- •clinical laboratory evaluations (including clinical chemistry panel \[fasted at least 10 hours\], CBC, and UA) within the reference range for the test laboratory, unless deemed not clinically significant by the Investigator;
- •negative test for selected drugs of abuse (including alcohol) at Screening and at Check-in;
- •negative hepatitis panel (including hepatitis B surface antigen \[HBsAg\] and hepatitis C virus antibody \[anti-HCV\]) and negative HIV antibody screens;
- •females of childbearing potential must be non-pregnant and non-lactating, and agree to use contraception from the time of signing the informed consent or 10 days prior to Check-in (Day -1) until 30 days after the final dose administration. One of the following forms of contraception must be used from the time of signing the informed consent or 10 days prior to Check-in (Day -1) until 30 days after the final dose administration: non-hormonal intrauterine device (IUD) with spermicide; female condom with spermicide; contraceptive sponge with spermicide; intravaginal system (eg, NuvaRing®); diaphragm with spermicide; cervical cap with spermicide; male sexual partner who agrees to use a male condom with spermicide; sterile sexual partner; or abstinence. Oral, implantable, transdermal, or injectable hormonal contraceptives may not be used from the time of signing the informed consent or 10 days prior to Check-in (Day -1) until 14 days after the final dose administration. For all females, the pregnancy test result must be negative at Screening and Check-in (Day -1). Females not of childbearing potential must be postmenopausal for at least 1 year or surgically sterile (eg, tubal ligation, hysterectomy) for at least 90 days;
- •males will either be surgically sterile (ie, vasectomy, documented in the medical record by a physician) or agree to use from Check-in (Day -1) until 90 days following Study Completion (Day 19)/ET, one of the following approved methods of contraception: male condom with spermicide; sterile sexual partner; or use by female sexual partner of an IUD with spermicide, a female condom with spermicide, a contraceptive sponge with spermicide, an intravaginal system, a diaphragm with spermicide, a cervical cap with spermicide, or oral, implantable, transdermal, or injectable contraceptives. Subjects must agree to refrain from sperm donation from Check-in (Day -1) until 90 days following Study Completion (Day 19)/ET;
- •able to comprehend and willing to sign an Informed Consent Form (ICF).
Exclusion Criteria
- •history or clinical manifestation of clinically significant cardiovascular, pulmonary, hepatic (eg, hepatitis), renal, hematologic, gastrointestinal (eg, celiac disease, peptic ulcer, gastroesophageal reflux, inflammatory bowel disease), metabolic, allergic, dermatological, neurological, or psychiatric disorder (as determined by the Investigator; appendectomy and cholecystectomy are not considered to be clinically significant disease);
- •abnormalities in liver function tests (any/all of alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase \>1.5 × upper limit of normal \[ULN\]; gamma-glutamyl transferase \>2 × ULN; or total bilirubin \>1.3 × ULN) or kidney function tests (serum creatinine \> ULN) that are considered clinically significant by the Investigator, in consultation with the Sponsor;
- •history of malignancy, except the following; cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps;
- •history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, including clarithromycin, unless approved by the Investigator;
- •history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy and hernia repair will be allowed;
- •history of Gilbert's Syndrome;
- •history or presence of an abnormal ECG, which, in the Investigator's opinion, is clinically significant; QTcF \>450 msec, or factors that increase risk for QTc interval prolongation (eg, heart failure, hypokalemia \[defined as serum potassium \<3.0 mEq/L that is persistent and refractory to correction\], or family history of long QT interval syndrome)
- •history of alcoholism or drug addiction within 1 year prior to Check-in (Day -1);
- •use of tobacco- or nicotine-containing products within 6 months prior to Check-in (Day -1) and during the entire study;
- •consumption of alcohol- or caffeine-containing foods and beverages for 72 hours prior to Screening and during the entire study;
Arms & Interventions
Pacritinib and Clarithromycin
Single 400-mg (four 100-mg capsules; lot number 21341) oral doses of pacritinib were administered in the fasted state on Days 1 and 12. Twice daily, 500-mg (1 tablet) oral doses of clarithromycin were administered with or without food on Days 8 through 11 and in the fasted state on the morning of Day 12
Intervention: Pacritinib
Pacritinib and Clarithromycin
Single 400-mg (four 100-mg capsules; lot number 21341) oral doses of pacritinib were administered in the fasted state on Days 1 and 12. Twice daily, 500-mg (1 tablet) oral doses of clarithromycin were administered with or without food on Days 8 through 11 and in the fasted state on the morning of Day 12
Intervention: Clarithromycin
Pacritinib and Clarithromycin
Single 400-mg (four 100-mg capsules; lot number 21341) oral doses of pacritinib were administered in the fasted state on Days 1 and 12. Twice daily, 500-mg (1 tablet) oral doses of clarithromycin were administered with or without food on Days 8 through 11 and in the fasted state on the morning of Day 12
Intervention: Pacritinib and Clarithromycin
Outcomes
Primary Outcomes
Estimate ratios of geometric mean values and the corresponding 90% confidence intervals (CIs) for pacritinib treatments with and without clarithromycin
Time Frame: Fifteen days approximately
To estimate ratios of geometric mean values and the corresponding 90% confidence intervals
Secondary Outcomes
- The maximum plasma concentration (Cmax).(Plasma (Day 1 and 12): 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose)
- The time to reach maximum plasma concentration (tmax).(Plasma (Day 1 and 12): 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose)
- Incidence of Treatment-Emergent Adverse Events(from Day 1 to Day 19)
- The apparent terminal elimination rate constant (λZ) and the respective apparent terminal elimination half-life (t½).(Plasma (Day 1 and 12): 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose)
- The area under the plasma concentration-time curve from time zero to time of the last measured concentration above the limit of quantification (AUC0-t)(Plasma (Day 1 and 12): 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose)
- The area under the plasma concentration-time curve from zero to infinity (AUC0-∞).(Plasma (Day 1 and 12): 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose)
- The apparent volume of distribution (Vd).(Plasma (Day 1 and 12): 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose)
- The apparent total body clearance (CL/F).(Plasma (Day 1 and 12): 0, 1, 2, 4, 6, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 144, and 168 hrs post-dose)